

Supplemental Table 3. Examples* of non-progressive and progressive heteroresistance in different antibiotic classes

Antibiotic Class	Non-progressive HR	Progressive HR	Transition to Resistance	Transition to Susceptibility
Quinolones	<i>gyrA</i> mutations (nalidixic acid)	<i>gyrA</i> mutations (fluoroquinolones) <i>gyrA+parC</i> mutations (fluoroquinolones) <i>gyrA</i> and efflux pumps amplifications (nalidixic acid)	Fast	Slow, but fast in amplification
Aminoglycosides	<ul style="list-style-type: none"> • <i>rpsL</i> mutations (streptomycin) • <i>16S rRNA</i> A1402G mutation (kanamycin, gentamicin, and spectinomycin) 	<ul style="list-style-type: none"> • <i>aadB</i> amplifications • <i>aac(3)IId</i> amplifications 	Fast	Slow, but fast when either RpsL K43T compensatory mutation occurs for streptomycin or in amplification events
Beta-lactams	<ul style="list-style-type: none"> • Penicillin binding proteins (PBPs) • Outer membrane porin <i>oprD</i> (carbapenems) 	<ul style="list-style-type: none"> • Beta-lactamases <i>bla</i>TEM-1, TEM-10, and TEM-12 mutations • Beta-lactamase amplification • PBPs mutations • <i>oprD</i> mutations in combination with efflux pump mutations (carbapenems) 	Fast	Fast or slow, depending on associated fitness cost
Macrolides	<ul style="list-style-type: none"> • <i>23S rRNA</i> mutations • L4, L22 ribosomal mutations 	<ul style="list-style-type: none"> • Overproduction or mutations in efflux pumps • Progressive predominance of L4, L22 mutated ribosomes 	Fast with low rRNA copy number	Fast due to high fitness cost
Rifampin	<ul style="list-style-type: none"> • <i>rpoB</i> mutations 		Fast	Fast due to <i>tufA</i> or <i>rpoB</i> Y526H compensatory mutations
Trimethoprim	<ul style="list-style-type: none"> • <i>folA</i> mutations 	<ul style="list-style-type: none"> • Stepwise <i>folA</i> mutations 	Fast	Slow
Linezolid		<ul style="list-style-type: none"> • Single nucleotide transversion in <i>23S rRNA</i> (typically G2576) leading to recombination with other 	Slow	Fast

		copies of the gene (gene conversion)		
Fusidic acid	<ul style="list-style-type: none"> • <i>fusA</i> mutations 		Fast	Fast
Lipo and glycopeptides		<ul style="list-style-type: none"> • Mutations in <i>mprF</i>, <i>yycFG</i> operon and genes encoding subunits of RNA polymerase • Amplification of <i>pmrD</i>, regulating genes encoding proteins that modify lipid A 	Slow	Fast due to high fitness cost
Mupirocin	<ul style="list-style-type: none"> • <i>ileS</i> mutations 	<ul style="list-style-type: none"> • Consecutive mutations in <i>ileS</i> 	Fast	Slow
Fosfomycin	<ul style="list-style-type: none"> • Mutations in <i>murA</i>, <i>uhpT</i>, and <i>glpT</i> 		Fast (in the absence of glucose-6 phosphate)	Fast
Tigecycline Tetracyclines		<ul style="list-style-type: none"> • Overproduction of efflux pumps AcrAB–TolC, OqxAB, and MacAB • Sequential mutations in <i>ramR</i>, <i>lon</i>, and <i>rpsJ</i> • Amplification of <i>tet(A)</i> 	Fast	Fast

* Details and further references about above examples of mentioned resistance mechanisms can be found in: Baquero F, Martínez JL, F Lanza V, Rodríguez-Beltrán J, Galán JC, San Millán A, Cantón R, Coque TM. (2021) Evolutionary Pathways and Trajectories in Antibiotic Resistance. *Rev Clin Microbiol.* 34(4):e0005019, and Pereira, C., Larsson, J., Hjort, K., Elf, J., Andersson, D. I. (2021). The highly dynamic nature of bacterial heteroresistance impairs its clinical detection. *Communications Biology*, 4(1), 521.